INAB · In8bio, Inc.
$1.11
-0.08 (-6.72%)
At close · Jul 28
Going-concern doubt
— flagged May 7, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on the Company’s business strategy, its existing cash of $21.9 million as of March 31, 2026 is not anticipated to fund the Company’s projected operating expenses and capital expenditure requirements for a period of at least 12 months from the date of issuance of these condensed financial statements, and accordingly, there is substantial doubt about the Company’s ability to continue to operate as a going concern.”View the 10-Q filed May 7, 2026
Market Cap
$10.93M
Shares
9.85M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| William Ho | CEO | $953,720 |
| Kate Rochlin | COO | $688,850 |
| Patrick McCall | CFO | $677,196 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| William Ho | CEO | $1,453,512 |
| Kate Rochlin | COO | $790,083 |
| Patrick McCall | CFO | $780,377 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| William Ho | CEO | $1,854,166 |
| Trishna Goswami | Chief Medical Officer | $1,065,676 |
| Patrick McCall | CFO | $914,843 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| William Ho | CEO | $1,729,646 |
| Trishna Goswami | Chief Medical Officer | $999,307 |
| Kate Rochlin | COO | $934,681 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| William Ho | CEO | $2,291,689 |
| Patrick McCall | CFO | $1,520,333 |
| Lawrence Lamb | Executive Vice President, Chief Scientific Officer, and Co-Founder | $918,754 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Lawrence Lamb | Executive Vice President, Chief Scientific Officer, and Co-Founder | $1,676,810 |
| William Ho | CEO | $1,447,707 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Corinne Epperly | Class II director | Appointed | 2026-05-07 |
| Peter Brandt | Class II director | Appointed | 2026-05-07 |
| Jeremy Graff | Interim Chair of the Board | Appointed | 2026-02-27 |
| Alan S. Roemer | director | Resigned | 2026-02-27 |